AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

#CART

4 people · 4 posts

Records

Drug / trial	Readout	Setting
CAR-PRISM#CART #MMSM	20/20 MRD-negative; no progression at 15.3 mo median follow-up	High-risk smoldering myeloma · concurrent Nature Medicine
EGFRvIII CAR#CART #CARTCELL	13 patients: 2 PR, 7 SD	GBM · June plenary

CAR-PRISM’s universal MRD negativity happened in a window of healthier T cells and lower burden; solid tumors do not have that window yet.

Other cases in this chapter

autogene cevumeran7 of 8 responders alive at 4–6 years; 2 of 8 non-responders
mRNA-4157Melanoma RFS HR 0.44
局部 nivolumabOral pre-cancer clinical response 85%, 1-year clearance 82%

Floor

Apr 23Thu

Thursday · 1 items

00:13
x.com@Score6060
Janos Tanyi, MD, PhD, shared new #CART research at #AACR26 this week. The first of its kind Phase I clinical trial uses a KIR-CAR modeled...
Same topic #CART · 4 peopleHeat 11 like0 replies0 reposts

Apr 21Tue

Tuesday · 2 items

05:20
Yi Lin@YiLinMDPhDScore6060
Happening now, Dr. Melinda Tan shares our finding on metabolic profiles of immune cells associated with clinical response to #CART #lymsm...
Same topic #CART · 4 people #LYMSMHeat 44 likes0 replies0 reposts
03:03
Penn Medicine@PennMedicineScore6060
Janos L. Tanyi, MD, PhD, shared new #CART research at #AACR26 today. The first-of-its-kind Phase I clinical trial uses a KIR-CAR modeled ...
Same topic #CART · 4 peopleHeat 108 likes0 replies2 reposts

Apr 20Mon

Monday · 1 items

23:21
Allogene Therapeutics@AllogeneTxScore6060
The Allogene team is at #AACR26! Today, we’re presenting data on allogeneic BCMA/CD70 dual #CART cells as a potential off-the-shelf optio...
Same topic #CART · 4 people #CELLTHERAPY #ALLOGENEICHeat 1916 likes1 reply2 reposts